Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vascular Cell Activation, Cell-Derived Microparticles and In Vitro Fertilisation, and In Vitro Fertilisation (PREDHSO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03051230
Recruitment Status : Completed
First Posted : February 13, 2017
Last Update Posted : February 13, 2017
Sponsor:
Collaborator:
Agence de La Biomédecine
Information provided by (Responsible Party):
Antoine Torre, Poissy-Saint Germain Hospital

Tracking Information
First Submitted Date February 1, 2017
First Posted Date February 13, 2017
Last Update Posted Date February 13, 2017
Actual Study Start Date April 1, 2012
Actual Primary Completion Date January 2, 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: February 8, 2017)
  • Quantification of Microparticles subsets from endothelial origin in the circulating blood [ Time Frame: At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Microparticles subsets from erythrocyte origin in the circulating blood [ Time Frame: At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Microparticles subsets from leukocyte origin in the circulating blood [ Time Frame: At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Microparticles subsets from platelet origin in the circulating blood [ Time Frame: At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Tissue Factor-Dependent Procoagulant Activity (MP-TF) in the circulating blood [ Time Frame: At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal ]
    Venipuncture for blood sampling and exam with home made device
  • Quantification of Plasmin Generation Capacity (MP-PGC) in the circulating blood [ Time Frame: At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal ]
    Venipuncture for blood sampling and exam with home made device
  • Quantification of Fibrin monomer in the circulating blood [ Time Frame: At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of D-dimer in the circulating blood [ Time Frame: At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of E-selectin in the circulating blood [ Time Frame: At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of soluble CD 146 in the circulating blood [ Time Frame: At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of Von Willbrand factor in the circulating blood [ Time Frame: At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of thrombin-antithrombin complex in the circulating blood [ Time Frame: At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of prothrombin fragment 1+2 in the circulating blood [ Time Frame: At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of Microparticles subsets from endothelial origin in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Microparticles subsets from erythrocyte origin in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Microparticles subsets from leukocyte origin in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Microparticles subsets from platelet origin in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Tissue Factor-Dependent Procoagulant Activity (MP-TF) in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation ]
    Venipuncture for blood sampling and exam with home made device
  • Quantification of Plasmin Generation Capacity (MP-PGC) in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation ]
    Venipuncture for blood sampling and exam with home made device
  • Quantification of Fibrin monomer in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of D-dimer in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of E-selectin in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of soluble CD 146 in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of Von Willbrand factor in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of thrombin-antithrombin complex in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of prothrombin fragment 1+2 in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of Microparticles subsets from endothelial origin in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when ≥ 3 ovarian follicles rich 17mm ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Microparticles subsets from erythrocyte origin in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when ≥ 3 ovarian follicles rich 17mm ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Microparticles subsets from leukocyte origin in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when ≥ 3 ovarian follicles rich 17mm ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Microparticles subsets from platelet origin in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when ≥ 3 ovarian follicles rich 17mm ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Tissue Factor-Dependent Procoagulant Activity (MP-TF) in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when ≥ 3 ovarian follicles rich 17mm ]
    Venipuncture for blood sampling and exam with home made device
  • Quantification of Plasmin Generation Capacity (MP-PGC) in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when ≥ 3 ovarian follicles rich 17mm ]
    Venipuncture for blood sampling and exam with home made device
  • Quantification of Fibrin monomer in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when ≥ 3 ovarian follicles rich 17mm ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of D-dimer in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when ≥ 3 ovarian follicles rich 17mm ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of E-selectin in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when ≥ 3 ovarian follicles rich 17mm ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of soluble CD 146 in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when ≥ 3 ovarian follicles rich 17mm ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of Von Willbrand factor in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when ≥ 3 ovarian follicles rich 17mm ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of thrombin-antithrombin complex in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when ≥ 3 ovarian follicles rich 17mm ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of prothrombin fragment 1+2 in the circulating blood [ Time Frame: During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when ≥ 3 ovarian follicles rich 17mm ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of Microparticles subsets from endothelial origin in the circulating blood [ Time Frame: 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Microparticles subsets from erythrocyte origin in the circulating blood [ Time Frame: 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Microparticles subsets from leukocyte origin in the circulating blood [ Time Frame: 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Microparticles subsets from platelet origin in the circulating blood [ Time Frame: 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Tissue Factor-Dependent Procoagulant Activity (MP-TF) in the circulating blood [ Time Frame: 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos ]
    Venipuncture for blood sampling and exam with home made device
  • Quantification of Plasmin Generation Capacity (MP-PGC) in the circulating blood [ Time Frame: 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos ]
    Venipuncture for blood sampling and exam with home made device
  • Quantification of Fibrin monomer in the circulating blood [ Time Frame: 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of D-dimer in the circulating blood [ Time Frame: 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of E-selectin in the circulating blood [ Time Frame: 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of soluble CD 146 in the circulating blood [ Time Frame: 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of Von Willbrand factor in the circulating blood [ Time Frame: 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of thrombin-antithrombin complex in the circulating blood [ Time Frame: 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of prothrombin fragment 1+2 in the circulating blood [ Time Frame: 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of Microparticles subsets from endothelial origin in the circulating blood [ Time Frame: 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Microparticles subsets from erythrocyte origin in the circulating blood [ Time Frame: 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Microparticles subsets from leukocyte origin in the circulating blood [ Time Frame: 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Microparticles subsets from platelet origin in the circulating blood [ Time Frame: 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Tissue Factor-Dependent Procoagulant Activity (MP-TF) in the circulating blood [ Time Frame: 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase ]
    Venipuncture for blood sampling and exam with home made device
  • Quantification of Plasmin Generation Capacity (MP-PGC) in the circulating blood [ Time Frame: 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase ]
    Venipuncture for blood sampling and exam with home made device
  • Quantification of Fibrin monomer in the circulating blood [ Time Frame: 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of D-dimer in the circulating blood [ Time Frame: 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of E-selectin in the circulating blood [ Time Frame: 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of soluble CD 146 in the circulating blood [ Time Frame: 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of Von Willbrand factor in the circulating blood [ Time Frame: 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of thrombin-antithrombin complex in the circulating blood [ Time Frame: 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of Microparticles subsets from platelet origin in the circulating blood [ Time Frame: 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of Microparticles subsets from endothelial origin in the circulating blood [ Time Frame: 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Microparticles subsets from erythrocyte origin in the circulating blood [ Time Frame: 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Microparticles subsets from leukocyte origin in the circulating blood [ Time Frame: 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Microparticles subsets from platelet origin in the circulating blood [ Time Frame: 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test ]
    Venipuncture for blood sampling and exam with flow cytometry
  • Quantification of Tissue Factor-Dependent Procoagulant Activity (MP-TF) in the circulating blood [ Time Frame: 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test ]
    Venipuncture for blood sampling and exam with home made device
  • Quantification of Plasmin Generation Capacity (MP-PGC) in the circulating blood [ Time Frame: 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test ]
    Venipuncture for blood sampling and exam with home made device
  • Quantification of Fibrin monomer in the circulating blood [ Time Frame: 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of D-dimer in the circulating blood [ Time Frame: 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of E-selectin in the circulating blood [ Time Frame: 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of soluble CD 146 in the circulating blood [ Time Frame: 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of Von Willbrand factor in the circulating blood [ Time Frame: 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of thrombin-antithrombin complex in the circulating blood [ Time Frame: 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test ]
    Venipuncture for blood sampling and exam with commercial device
  • Quantification of prothrombin fragment 1+2 in the circulating blood [ Time Frame: 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test ]
    Venipuncture for blood sampling and exam with commercial device
Original Primary Outcome Measures Same as current
Change History No Changes Posted
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Vascular Cell Activation, Cell-Derived Microparticles and In Vitro Fertilisation, and In Vitro Fertilisation
Official Title Vascular Cell Activation Throughout Ovarian Hyperstimulation for In Vitro Fertilisation: Role of Cell-Derived Microparticles in the Adverse Outcomes
Brief Summary

Introduction: Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic phenomenon, poorly understood and difficult to predict, complicating intense ovarian stimulation cycle. The most severe symptoms, which associate vascular permeability disorders and hypercoagulability, occur in 0.2 to 1% of the cases and often require intensive care.

Activation of endothelial, platelet, erythrocyte or leukocyte cells trigger the release of small specific vesicles, called microparticles, used as markers.

Classically leading to endothelial dysfunction and hypercoagulability, the endothelial activation phenomenon could constitute the main cause of OHSS or help predict its severity, as established for various other diseases (cerebral stroke, infarct and lupus…). However, so far, this endothelial activation role has never been studied.

Objectives:

Evaluate the serum level of microparticles as a predictor of adverse outcomes; correlate it to hypercoagulability and changes of endothelial permeability associated with this syndrome.

Methodology: Prospective Pilote Cohort study, evaluating before and throughout the ovarian stimulation cycle (6 samples/patient), the serum modulation of:

  • Endothelial activation markers (endothelial-derived microparticles, E-selectin)
  • Procoagulant markers (microparticles from platelet, erythrocyte or leukocyte origin, Von Willbrand factor, thrombin-antithrombin complex, prothrombin fragment 1+2)
  • Endothelial disjunction marker (soluble CD 146) A group of 50 patients will be assessed Techniques: Flow cytometry for measurement of microparticles expressing non specific (Annexin V) and cell specific surface determinants (CD 31, CD 41, CD 45 or glycophorin A). Use of commercial kits for other serum markers.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples Without DNA
Description:
After platelet removal, serum samples will be frozen stored before being processed
Sampling Method Probability Sample
Study Population Infertile volunteers, aged 18 to 35 years, with neither cardiovascular disease nor Lupus erythematosus related disease, scheduled for In Vitro fertilisation, and assessed from their day 3 basal hormonal assessment, at least to the ovarian triggering of their IVF cycle were included.
Condition
  • Infertility
  • Hyperstimulation Syndrome, Ovaian
  • Thrombosis
Intervention Not Provided
Study Groups/Cohorts Studied group
Women exposed to ovarian hyperstimulation for In Vitro fertilisation
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: February 8, 2017)
50
Original Actual Enrollment Same as current
Actual Study Completion Date February 1, 2017
Actual Primary Completion Date January 2, 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Between 18 and 35 years old
  • With Health Insurance
  • Scheduled for their first ovarian stimulation in an IVF or ICSI program in our centre
  • Whose blood samples will be collected in our hospital

Exclusion Criteria:

  • Suffering or having suffered from a disease likely to alter their vascular system and thus modulate their rates of microparticles:

    • auto-immune disease (systemic lupus erythematosus26, antiphospholipid syndrome)
    • cardiovascular risk factors: cardiovascular disease history, diabetes, arterial hypertension, dyslipidemia
    • Tobacco addiction.
  • Presenting a blood œstradiol rate > 5000 pg/ml at ovulation triggering (criterion of stimulation cancellation) and more generally, every patient which ovulation has not been triggered.
Sex/Gender
Sexes Eligible for Study: Female
Ages 18 Years to 43 Years   (Adult)
Accepts Healthy Volunteers Not Provided
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT03051230
Other Study ID Numbers PREDHSO
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: Undecided
Responsible Party Antoine Torre, Poissy-Saint Germain Hospital
Study Sponsor Poissy-Saint Germain Hospital
Collaborators Agence de La Biomédecine
Investigators Not Provided
PRS Account Poissy-Saint Germain Hospital
Verification Date February 2017